Indaptus Therapeutics Croissance future

Future contrôle des critères 0/6

Indaptus Therapeutics devrait augmenter ses bénéfices et ses revenus de 12.9% et de 85% par an respectivement, tandis que le BPA devrait croître de croître de 31.7% par an.

Informations clés

12.9%

Taux de croissance des bénéfices

31.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.1%
Taux de croissance des recettes	85.0%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	16 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

Mar 27

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Aug 15

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Aug 08

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

Sep 29

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:INDP - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-24	N/A	N/A	1
12/31/2025	N/A	-22	N/A	N/A	2
12/31/2024	N/A	-18	N/A	N/A	2
6/30/2024	N/A	-16	-13	-13	N/A
3/31/2024	N/A	-15	-12	-12	N/A
12/31/2023	N/A	-15	-13	-13	N/A
9/30/2023	N/A	-15	-13	-13	N/A
6/30/2023	N/A	-15	-14	-14	N/A
3/31/2023	N/A	-15	-15	-15	N/A
12/31/2022	N/A	-14	-13	-13	N/A
9/30/2022	N/A	-14	-14	-14	N/A
6/30/2022	N/A	-14	-15	-15	N/A
3/31/2022	N/A	-10	-14	-14	N/A
12/31/2021	N/A	-8	-11	-11	N/A
9/30/2021	N/A	-5	-9	-9	N/A
6/30/2021	N/A	-3	-4	-4	N/A
3/31/2021	N/A	-4	-4	-4	N/A
12/31/2020	N/A	-4	-3	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: INDP devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: INDP devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: INDP devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: INDP ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: INDP ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de INDP devrait être élevé dans 3 ans

Indaptus Therapeutics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 15% to US$15.00

Price target decreased to US$11.00

Recent updates

Indaptus Therapeutics, Inc. Provides Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

New minor risk - Shareholder dilution

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000003 million.

Indaptus Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.3 million.

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

New major risk - Financial position

New minor risk - Share price stability

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial

Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20

Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023

Price target increased by 15% to US$15.00

Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of Directors

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Price target decreased to US$11.00

High number of new and inexperienced directors

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Indaptus Therapeutics, Inc., Annual General Meeting, Sep 29, 2022

CEO & Director recently bought US$52k worth of stock

Indaptus Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

High number of new and inexperienced directors

High number of new and inexperienced directors

CEO & Director recently bought US$65k worth of stock

Insider recently bought US$691k worth of stock

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

CEO & Director recently bought US$84k worth of stock

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance